Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial

Authors:

Abstract
Background: Influenza A (H7N9) has caused multiple disease waves with evidence of strain diversification. Optimal influenza A (H7N9) prime-boost vaccine strategies are unknown. Methods: We recruited participants who had received monovalent inactivated A/Shanghai/2/2013 (H7N9) vaccine (MIV) approximately 5 years earlier, as follows: MIV with MF59 (MF59 × 2 group), MIV with AS03 (AS03 × 2 group), unadjuvanted MIV (No Adj group), MIV with MF59 or AS03 followed by unadjuvanted MIV (Adjx1 group), and A/H7-naive (unprimed group). Participants were randomized to receive 1 dose of AS03-adjuvanted or unadjuvanted A/Hong Kong/125/2017 (H7N9) MIV and were followed for safety and immunogenicity using hemagglutination inhibition (HAI) and neutralizing antibody assays. Results: We enrolled 304 participants: 153 received the adjuvanted boost and 151 received the unadjuvanted boost. At 21 days postvaccination, the proportion of participants with HAI antibody titers against the boosting vaccine strain of ≥40 in the adjuvanted and unadjuvanted arms, respectively, were 88% and 49% in MF59 × 2 group, 89% and 75% in AS03 × 2 group, 59% and 20% in No Adj group, 94% and 55% in Adjx1group, and 9% and 11% in unprimed group. Conclusions: Serologic responses to a heterologous A(H7N9) MIV boost were highest in participants primed and boosted with adjuvant-containing regimens. Clinical Trials Registration: NCT03738241.
Funding Information
  • Division of Microbiology and Infectious Diseases
  • National Institutes of Health (HHSN272201300015I, HHSN272201300018I, HHSN272201300021I, HHSN272201300020I, HHSN272201300019I, HHSN272201300016I, HHSN272201300023I, HHSN272201300022I, 75N93021C00012)
  • Institute for Clinical and Translational Research, University of Maryland, Baltimore;
  • National Center for Advancing Translational Sciences (1UL1TR003098)
  • General Clinical Research Center, University of Maryland
  • Department of Health and Human Services
  • Administration for Strategic Preparedness and Response
  • Biomedical Advanced Research and Development Authority (HHSO100201600006I, HHSO1002012000131I, HHSO100201600004I)
  • Sanofi Pasteur
  • GSK

This publication has 25 references indexed in Scilit: